“We are pleased to report continuous clinical development progress across our entire pipeline of Precision Endocrine Peptide product candidates with a number of value-creating milestones anticipated in the second half of this year,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences (MBX). “We look forward to sharing topline results from our Phase 2 Avail trial of canvuparatide in hypoparathyroidism this quarter. In addition, we are on track to initiate a Phase 2a clinical trial for imapextide, a peptide therapy for the treatment of post-bariatric hypoglycemia, and a Phase 1 trial evaluating MBX 4291 in patients with obesity, both in this quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Block downgraded, Wayfair upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Mizuho
- Arm, Palantir upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Oppenheimer
- MBX Biosciences appoints Andreas Moraitis as SVP, clinical development